Reducing barriers to patient enrollment in cancer clinical trials
Clinical trials are the key step in advancing potential new cancer treatments out of the lab and into the clinic. Patient participation in trials is crucial to this success. \n\nBut only a small fraction of patients end up enrolling in a cancer clinical trial due to barriers that make participation difficult or even impossible. As a result, approximately 20% of cancer clinical trials fail due to insufficient patient enrollment. Understanding and addressing these barriers is critical to accelerating progress in cancer research.\n\nMark Fleury, PhD, is Policy Principal at ACS CAN \u2013 the American Cancer Society Cancer Action Network (https://www.fightcancer.org/). Dr. Fleury joined the podcast to help us understand where we are falling short and how we can reduce these barriers to patient enrollment in clinical trials.\n\n5:36 \u2013 What is ACS CAN?\n\n7:55 \u2013 A recent piece of cancer-related legislation where ACS CAN was involved that he is particularly proud of \n\n13:07 \u2013 Why clinical trials in cancer research are so important to patients\n\n16:23 \u2013 On barriers to clinical trial enrollment: ACS CAN resources note that \u201capproximately 20% of cancer clinical trials fail due to insufficient patient enrollment.\u201d Why are we falling short? \n\n22:50 \u2013 Some of the recommendations ACS CAN has helped identify that would reduce barriers to enrollment in cancer clinical trials \n\n27:04 \u2013 How clinical trial matching services could be improved \n\n32:38 \u2013 On disparities in clinical trial participation